Indaptus Therapeutics 3Q 2026: EPS ($0.01) — 10-Q Summary
Indaptus Therapeutics reported a 65% narrower net loss YoY for 3Q 2026, with expenses falling due to reduced clinical activity and payroll costs. R&D expenses dropped 82% to $271,204, while G&A expenses declined 24% to $864,663. The company discontinued further enrollment in its Decoy20 study and began a new research collaboration with Kunming University of Science and Technology.
How this was made

The 30-second read
Why it matters
The disclosed financial improvements may prompt short‑term price appreciation, but ongoing clinical uncertainty tempers upside.
Market read
First‑time quarterly data for a micro‑cap biotech; relevance primarily to sector‑focused traders.
What to watch
Potential upcoming clinical trial setbacks or funding needs could offset short‑term cost improvements.
Background
Indaptus Therapeutics filed its Q3 2026 10‑Q, highlighting a narrowed net loss and discontinued clinical enrollment.
Ticker impact
10-Q filing shows net loss narrowed 65% YoY and EPS improved to -$0.01, the first report of these quarterly results.
potential modest upside as the market prices in the narrowed loss and expense cuts
The company still reports a loss, but the sharp decline in expenses and loss improvement are new data that can shift sentiment.
Market effects
Biotech peers may be re‑rated as cost‑control becomes a focus.
U.S. small‑cap biotech segment could see slight positive pressure.
Limited to investors tracking early‑stage biotech earnings.
Counterpoint
The loss remains material; investors may stay cautious despite expense cuts.
Key entities
- companyIndaptus Therapeutics, Inc.
U.S. listed biotech (ticker INDP) reporting Q3 2026 results.

